
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5772240/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<scp>Longâ€term</scp> efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled <scp>52â€week</scp> outcomes from the <scp>DEPICT</scp> â€1 and â€2 studies. Diabetes, Obesity and Metabolism, 2021, 23, 549-560.	2.2	21
2	Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors. Diabetes, Obesity and Metabolism, 2021, 23, 1614-1623.	2.2	13
3	Diabetes, Obesity, COVID-19, Insulin, and Other Antidiabetes Drugs. Diabetes Care, 2021, 44, 1929-1933.	4.3	12
4	4-Phenylbutyric acid improves free fatty acid-induced hepatic insulin resistance in vivo. Endocrine Connections, 2021, 10, 861-872.	0.8	6
5	Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review. Diabetes, Obesity and Metabolism, 2021, 23, 18-28.	2.2	34
6	The side effects of immune checkpoint inhibitor therapy on the endocrine system. Indian Journal of Medical Research, 2021, 154, 559.	0.4	7
7	Intravenous Insulin Versus Conservative Management in Hypertriglyceridemia-Associated Acute Pancreatitis. Journal of the Endocrine Society, 2020, 4, bvz019.	0.1	21
8	Testosterone Increases the Expression and Phosphorylation of AMP Kinase \hat{I}_{\pm} in Men With Hypogonadism and Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1169-1175.	1.8	23
9	Bariatric Surgery: Remission of Inflammation, Cardiometabolic Benefits, and Common Adverse Effects. Journal of the Endocrine Society, 2020, 4, bvaa049.	0.1	22
10	Benefit/risk profile of dapagliflozin 5 mg in the <scp>DEPICT</scp> â€1 and â€2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m ² . Diabetes, Obesity and Metabolism, 2020, 2151-2160.	2 2, 2	23
11	Effective Initiation and Treatment With Basal Insulin in People With Type 2 Diabetes: Focus on Mitigating Hypoglycemia in Patients at Increased Risk: Executive Summary. Clinical Diabetes, 2020, 38, 324-327.	1.2	0
12	Narcolepsy, depression, and severe flushing in an obese man. Clinical Case Reports (discontinued), 2020, 8, 1824-1826.	0.2	1
13	Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2020, 8, 845-854.	5.5	46
14	Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26â€week randomized controlled trial; mechanisms of weight loss. Diabetes, Obesity and Metabolism, 2020, 22, 1742-1752.	2.2	32
15	Adjunct therapies in treatment of type 1 diabetes. Journal of Diabetes, 2020, 12, 742-753.	0.8	17
16	Remission of type 2 diabetes following longâ€ŧerm treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11â€year data from a realâ€world registry study. Diabetes, Obesity and Metabolism, 2020, 22, 2055-2068.	2.2	55
17	Longâ€ŧerm efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the <scp>DEPICT</scp> â€2 study): 52â€week results from a randomized controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 1516-1526.	2.2	38
18	Semaglutide in Cystic Fibrosis-Related Diabetes. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2341-2344.	1.8	8

#	ŧ	Article	IF	CITATIONS
1	19	Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1056-e1063.	1.8	113
2	20	Macronutrient-Mediated Inflammation and Oxidative Stress: Relevance to Insulin Resistance, Obesity, and Atherogenesis. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6118-6128.	1.8	58
2	21	Increase in Osteocalcin Following Testosterone Therapy in Men With Type 2 Diabetes and Subnormal Free Testosterone. Journal of the Endocrine Society, 2019, 3, 1617-1630.	0.1	10
2	22	Effect of Testosterone on FGF2, MRF4, and Myostatin in Hypogonadotropic Hypogonadism: Relevance to Muscle Growth. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2094-2102.	1.8	23
2	23	Liraglutide and systolic blood pressure. Journal of Clinical Hypertension, 2019, 21, 116-117.	1.0	1
2	24	Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2. Diabetes Care, 2019, 42, 1081-1087.	4.3	40
2	25	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care, 2019, 42, 1147-1154.	4.3	249
2	26	Addition of glucagonâ€like peptideâ€1 receptor agonist therapy to insulin in Câ€peptideâ€positive patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1054-1057.	2.2	12
2	27	Acute effects of insulin on skeletal muscle growth and differentiation genes in men with type 2 diabetes. European Journal of Endocrinology, 2019, 181, K55-K59.	1.9	6
2	28	274-LB: The Anti-inflammatory Effects of Insulin and Hydrocortisone Combination in Obese Subjects. Diabetes, 2019, 68, 274-LB.	0.3	1
2	29	Decreases in neprilysin and vasoconstrictors and increases in vasodilators following bariatric surgery. Diabetes, Obesity and Metabolism, 2018, 20, 2029-2033.	2.2	30
3	30	Diminished androgen and estrogen receptors and aromatase levels in hypogonadal diabetic men: reversal with testosterone. European Journal of Endocrinology, 2018, 178, 277-283.	1.9	31
3	31	Incretins: <scp>B</scp> eyond type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 59-67.	2.2	8
3	32	Macronutrient intake and oxidative stress/inflammation in type 1 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 247-248.	1.2	1
3	33	Exenatide Increases IL-1RA Concentration and Induces Nrf-2‒Keap-1‒Regulated Antioxidant Enzymes: Relevance to β-Cell Function. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1180-1187.	1.8	13
3	34	Intranasal Insulin Administration Does Not Affect LH Concentrations in Men with Diabetes. International Journal of Endocrinology, 2018, 2018, 1-7.	0.6	4
3	35	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. Diabetes Care, 2018, 41, 2552-2559.	4.3	177
3	36	Hypogonadotropic Hypogonadism in Men With Diabesity. Diabetes Care, 2018, 41, 1516-1525.	4.3	99

#	Article	IF	CITATIONS
37	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the) Tj ETQq1 1 ().784314 4.3	rgBT_/Overlo
38	Letter to the Editor: "Long-Term Testosterone Administration on Insulin Sensitivity in Older Men With Low or Low-Normal Testosterone Levels― Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2069-2070.	1.8	2
39	Dapagliflozin in patients with type 1 diabetes: <scp>A</scp> <i>post hoc</i> analysis of the effect of insulin dose adjustments on 24â€hour continuously monitored mean glucose and fasting l²â€hydroxybutyrate levels in a phase <scp>lla</scp> pilot study. Diabetes, Obesity and Metabolism, 2017, 19, 814-821.	2.2	34
40	Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician. International Journal of Clinical Practice, 2017, 71, e12937.	0.8	22
41	Antiinflammatory and ROS Suppressive Effects of the Addition of Fiber to a High-Fat High-Calorie Meal. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 858-869.	1.8	30
42	Exenatide induces an increase in vasodilatory and a decrease in vasoconstrictive mediators. Diabetes, Obesity and Metabolism, 2017, 19, 729-733.	2.2	19
43	Changes in Coronary Artery Plaque With Testosterone Therapy. JAMA - Journal of the American Medical Association, 2017, 317, 2450.	3.8	1
44	Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1306-1311.	2.2	22
45	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 864-876.	5.5	244
46	Ezetimibe and simvastatin combination inhibits and reverses the pro-inflammatory and pro-atherogenic effects of cream in obese patients. Atherosclerosis, 2017, 263, 278-286.	0.4	13
47	Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance. Diabetes Technology and Therapeutics, 2017, 19, 498-506.	2.4	48
48	Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes. Clinical Endocrinology, 2016, 85, 772-780.	1.2	33
49	Targeting AMP Kinase in Myeloid Cells to Reduce Atherosclerosis. Diabetes, 2016, 65, 1493-1495.	0.3	2
50	Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks. Diabetes Care, 2016, 39, 1027-1035.	4.3	80
51	Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3506-3515.	1.8	56
52	Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes. Diabetes Care, 2016, 39, 82-91.	4.3	214
53	Macronutrient intake, insulin secretion, oxidative stress & inflammation: Clinico-pathological implications. Indian Journal of Medical Research, 2016, 144, 645.	0.4	5
54	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Testosterone and Cardiovascular Risk. Endocrine Practice, 2015, 21, 1066-1073.	1.1	62

#	Article	IF	CITATIONS
55	Suppressive Effect of Insulin on the Gene Expression and Plasma Concentrations of Mediators of Asthmatic Inflammation. Journal of Diabetes Research, 2015, 2015, 1-7.	1.0	14
56	The effect of insulin to decrease neointimal growth after arterial injury is endothelial nitric oxide synthase-dependent. Atherosclerosis, 2015, 241, 111-120.	0.4	20
57	Distal small bowel bypass for weight regain after gastric bypass: safety and efficacy threshold occurs at<70% bypass. Surgery for Obesity and Related Diseases, 2015, 11, 1248-1255.	1.0	34
58	Decreased insulin secretion and incretin concentrations and increased glucagon concentrations after a high-fat meal when compared with a high-fruit and -fiber meal. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E185-E191.	1.8	16
59	Comment on Vandal et al. Insulin Reverses the High-Fat Diet–Induced Increase in Brain Aβ and Improves Memory in an Animal Model of Alzheimer Disease. Diabetes 2014;63:4291–4301. Diabetes, 2015, 64, e17-e17.	0.3	1
60	Prevalence of subnormal testosterone concentrations in men with type 2 diabetes and chronic kidney disease. European Journal of Endocrinology, 2015, 173, 359-366.	1.9	28
61	Nonesterified Fatty Acids, Albumin, and Platelet Aggregation. Diabetes, 2015, 64, 703-705.	0.3	19
62	Comment on Sarkar et al. Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes. Diabetes Care 2014;37:666–670. Diabetes Care, 2014, 37, e218-e218.	4.3	2
63	Oestradiol concentrations are not elevated in obesityâ€associated hypogonadotrophic hypogonadism. Clinical Endocrinology, 2014, 80, 464-464.	1.2	14
64	Deaths and Cardiovascular Events in Men Receiving Testosterone. JAMA - Journal of the American Medical Association, 2014, 311, 964.	3.8	8
65	Glycaemia and insulin after acute myocardial infarction. Nature Reviews Endocrinology, 2014, 10, 448-450.	4.3	3
66	Increase in the mediators of asthma in obesity and obesity with type 2 diabetes: Reduction with weight loss. Obesity, 2014, 22, 356-362.	1.5	46
67	Insulin infusion suppresses while glucose infusion induces Toll-like receptors and high-mobility group-B1 protein expression in mononuclear cells of type 1 diabetes patients. American Journal of Physiology - Endocrinology and Metabolism, 2013, 304, E810-E818.	1.8	46
68	Comment on: Rizzo et al. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076–2082. Diabetes Care, 2013, 36, e80-e80.	4.3	2
69	Intensive Glucose Control in Hyperglycemic Patients With Acute Coronary Syndromes. JAMA Internal Medicine, 2013, 173, 1905.	2.6	4
70	Testosterone concentrations in young pubertal and postâ€pubertal obese males. Clinical Endocrinology, 2013, 78, 593-599.	1.2	69
71	Liraglutide as Additional Treatment to Insulin in Obese Patients with Type 1 Diabetes Mellitus. Endocrine Practice, 2013, 19, 963-967.	1.1	63
72	Sitagliptin Exerts an Antinflammatory Action. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3333-3341.	1.8	212

PARESH DANDONA

#	Article	IF	CITATIONS
73	Exenatide Exerts a Potent Antiinflammatory Effect. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 198-207.	1.8	201
74	Reduction in Inflammation and the Expression of Amyloid Precursor Protein and Other Proteins Related to Alzheimer's Disease following Gastric Bypass Surgery. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1197-E1201.	1.8	46
75	Reduction in endotoxemia, oxidative and inflammatory stress, and insulin resistance after Roux-en-Y gastric bypass surgery in patients with morbid obesity and type 2 diabetes mellitus. Surgery, 2012, 151, 587-593.	1.0	126
76	Update: Hypogonadotropic Hypogonadism in Type 2 Diabetes and Obesity. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2643-2651.	1.8	244
77	Durability of Effects of Exenatide Treatment on Glycemic Control, Body Weight, Systolic Blood Pressure, C-Reactive Protein, and Triglyceride Concentrations. Endocrine Practice, 2011, 17, 192-200.	1.1	32
78	Insulin Suppresses the Expression of Amyloid Precursor Protein, Presenilins, and Glycogen Synthase Kinase-31² in Peripheral Blood Mononuclear Cells. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1783-1788.	1.8	18
79	Liraglutide as additional treatment for type 1 diabetes. European Journal of Endocrinology, 2011, 165, 77-84.	1.9	122
80	Low Estradiol Concentrations in Men With Subnormal Testosterone Concentrations and Type 2 Diabetes. Diabetes Care, 2011, 34, 1854-1859.	4.3	104
81	Prediction of adverse outcomes by blood glucose level after endovascular therapy for acute ischemic stroke. Journal of Neurosurgery, 2011, 114, 1785-1799.	0.9	34
82	A Novel Antihypertensive Effect of Exenatide, a GLP-1 Agonist. American Journal of Hypertension, 2010, 23, 228-228.	1.0	3
83	Suppressive Effect of Insulin Infusion on Chemokines and Chemokine Receptors. Diabetes Care, 2010, 33, 1103-1108.	4.3	50
84	Insulin Suppresses Endotoxin-Induced Oxidative, Nitrosative, and Inflammatory Stress in Humans. Diabetes Care, 2010, 33, 2416-2423.	4.3	58
85	Orange juice neutralizes the proinflammatory effect of a high-fat, high-carbohydrate meal and prevents endotoxin increase and Toll-like receptor expression. American Journal of Clinical Nutrition, 2010, 91, 940-949.	2.2	266
86	Testosterone Concentrations in Diabetic and Nondiabetic Obese Men. Diabetes Care, 2010, 33, 1186-1192.	4.3	286
87	Macronutrient intake induces oxidative and inflammatory stress: potential relevance to atherosclerosis and insulin resistance. Experimental and Molecular Medicine, 2010, 42, 245.	3.2	128
88	Differential Effects of Cream, Glucose, and Orange Juice on Inflammation, Endotoxin, and the Expression of Toll-Like Receptor-4 and Suppressor of Cytokine Signaling-3. Diabetes Care, 2010, 33, 991-997.	4.3	214
89	Rosiglitazone, thiazolidinediones and atherosclerosis. Atherosclerosis, 2010, 211, 384-385.	0.4	5
90	Hypogonadotropic Hypogonadism in Men with Type 2 Diabetes. Postgraduate Medicine, 2009, 121, 45-51.	0.9	35

#	Article	IF	CITATIONS
91	Increase in Plasma Endotoxin Concentrations and the Expression of Toll-Like Receptors and Suppressor of Cytokine Signaling-3 in Mononuclear Cells After a High-Fat, High-Carbohydrate Meal. Diabetes Care, 2009, 32, 2281-2287.	4.3	426
92	Insulin as an Anti-Inflammatory and Antiatherogenic Modulator. Journal of the American College of Cardiology, 2009, 53, S14-S20.	1.2	144
93	Vascular reactivity in diabetes mellitus. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2009, 56 Suppl 4, 12-4.	0.8	3
94	Use of Insulin to Improve Glycemic Control in Diabetes Mellitus. Cardiovascular Drugs and Therapy, 2008, 22, 241-251.	1.3	10
95	Potential use of insulin as an antiâ€inflammatory drug. Drug Development Research, 2008, 69, 101-110.	1.4	2
96	Thiazolidinediones—improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes. Journal of Diabetes and Its Complications, 2008, 22, 62-75.	1.2	19
97	Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein. Mayo Clinic Proceedings, 2008, 83, 333-342.	1.4	39
98	Acute Modulation of Toll-Like Receptors by Insulin. Diabetes Care, 2008, 31, 1827-1831.	4.3	116
99	Hypogonadotrophic Hypogonadism in Type 2 Diabetes, Obesity and the Metabolic Syndrome. Current Molecular Medicine, 2008, 8, 816-828.	0.6	79
100	Are thiazolidinediones associated with an increased risk of heart failure and cardiovascular death?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 244-245.	3.3	2
101	Testosterone Concentration in Young Patients With Diabetes. Diabetes Care, 2008, 31, 2013-2017.	4.3	113
102	Relationship of Prostate -Specific Antigen to Age and Testosterone in Men With Type 2 Diabetes Mellitus. Endocrine Practice, 2008, 14, 1000-1005.	1.1	15
103	The Effects of Hypogonadism on Body Composition and Bone Mineral Density in Type 2 Diabetic Patients. Diabetes Care, 2007, 30, 1860-1861.	4.3	43
104	Anti-inflammatory effects of insulin. Current Opinion in Clinical Nutrition and Metabolic Care, 2007, 10, 511-517.	1.3	105
105	Exenatide Therapy in Obese Patients With Type 2 Diabetes Mellitus Treated with Insulin. Endocrine Practice, 2007, 13, 444-450.	1.1	128
106	Antioxidant activity of carvedilol in cardiovascular disease. Journal of Hypertension, 2007, 25, 731-741.	0.3	137
107	Proinflammatory Effects of Glucose and Anti-Inflammatory Effect of Insulin: Relevance to Cardiovascular Disease. American Journal of Cardiology, 2007, 99, 15-26.	0.7	162
108	Effect of Hyperglycemia and Insulin in Acute Coronary Syndromes. American Journal of Cardiology, 2007, 99, S12-S18.	0.7	23

#	Article	IF	CITATIONS
109	Anti-Inflammatory Effects of Insulin and the Pro-Inflammatory Effects of Glucose. Seminars in Thoracic and Cardiovascular Surgery, 2006, 18, 293-301.	0.4	36
110	Anti-inflammatory and antiatherogenic effects of insulin. Insulin, 2006, 1, S11-S17.	0.2	3
111	Glucose ingestion induces an increase in intranuclear nuclear factor κB, a fall in cellular inhibitor κB, and an increase in tumor necrosis factor α messenger RNA by mononuclear cells in healthy human subjects. Metabolism: Clinical and Experimental, 2006, 55, 1177-1185.	1.5	138
112	Oxidative Inflammatory Stress in Obesity and Diabetes. , 2006, , 307-316.		0
113	The metabolic syndrome: linking oxidative stress and inflammation to obesity, type 2 diabetes, and the syndrome. Drug Development Research, 2006, 67, 619-626.	1.4	10
114	Low Testosterone and High C-Reactive Protein Concentrations Predict Low Hematocrit in Type 2 Diabetes. Diabetes Care, 2006, 29, 2289-2294.	4.3	110
115	Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care, 2006, 29, 1120-2.	4.3	41
116	Anti-inflammatory effects of insulin and pro-inflammatory effects of glucose: relevance to the management of acute myocardial infarction and other acute coronary syndromes. Reviews in Cardiovascular Medicine, 2006, 7 Suppl 2, S25-34.	0.5	9
117	Use of Continuous Subcutaneous Insulin Infusion Pump in Patients With Type 2 Diabetes Mellitus. The Diabetes Educator, 2005, 31, 843-848.	2.6	17
118	Metabolic Syndrome. Circulation, 2005, 111, 1448-1454.	1.6	1,157
119	Insulin infusion in acute illness. Journal of Clinical Investigation, 2005, 115, 2069-2072.	3.9	127
120	Glucose intake induces an increase in activator protein 1 and early growth response 1 binding activities, in the expression of tissue factor and matrix metalloproteinase in mononuclear cells, and in plasma tissue factor and matrix metalloproteinase concentrations. American Journal of Clinical Nutrition, 2004, 80, 51-57.	2.2	148
121	Classical Anti-oxidants (Scavengers) versus Biological Anti-oxidants (Suppressors of ROS Generation): ANovel Way to Explain the Anti-oxidant Paradox. Metabolic Syndrome and Related Disorders, 2004, 2, 155-159.	0.5	3
122	Circulating Mononuclear Cells in the Obese Are in a Proinflammatory State. Circulation, 2004, 110, 1564-1571.	1.6	576
123	Anti-Inflammatory and Profibrinolytic Effect of Insulin in Acute ST-Segment–Elevation Myocardial Infarction. Circulation, 2004, 109, 849-854.	1.6	280
124	Evidence for a Potent Antiinflammatory Effect of Rosiglitazone. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2728-2735.	1.8	355
125	Increased Plasma Concentration of Macrophage Migration Inhibitory Factor (MIF) and MIF mRNA in Mononuclear Cells in the Obese and the Suppressive Action of Metformin. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5043-5047.	1.8	167
126	Do Thiazolidinediones Exert Their Insulin-Sensitizing Effect Through the Suppression of Free Fatty Acids?. Metabolic Syndrome and Related Disorders, 2004, 2, 287-289.	0.5	0

#	Article	IF	CITATIONS
127	Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents. Journal of Diabetes and Its Complications, 2004, 18, 91-102.	1.2	21
128	Endothelial Dysfunction, Inflammation and Diabetes. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 189-197.	2.6	69
129	Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5462-5468.	1.8	546
130	Insulin Is an Anti-inflammatory and Anti-atherosclerotic Hormone. Metabolic Syndrome and Related Disorders, 2004, 2, 137-142.	0.5	12
131	Endothelial dysfunction and hypertension in diabetes mellitus. Medical Clinics of North America, 2004, 88, 911-931.	1.1	35
132	Inflammation: the link between insulin resistance, obesity and diabetes. Trends in Immunology, 2004, 25, 4-7.	2.9	1,812
133	Increase in intranuclear nuclear factor l̂ºB and decrease in inhibitor l̂ºB in mononuclear cells after a mixed meal: evidence for a proinflammatory effect. American Journal of Clinical Nutrition, 2004, 79, 682-690.	2.2	224
134	Insulin as an anti-inflammatory and antiatherosclerotic hormone. Clinical Cornerstone, 2003, 5, S13-S20.	1.0	43
135	Vascular reactivity and thiazolidinediones. American Journal of Medicine, 2003, 115, 81-86.	0.6	27
136	Elevation of Free Fatty Acids Induces Inflammation and Impairs Vascular Reactivity in Healthy Subjects. Diabetes, 2003, 52, 2882-2887.	0.3	546
137	The Potential Influence of Inflammation and Insulin Resistance on the Pathogenesis and Treatment of Atherosclerosis-Related Complications in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 2422-2429.	1.8	120
138	Insulin Suppresses Plasma Concentration of Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9. Diabetes Care, 2003, 26, 3310-3314.	4.3	96
139	The Potential Therapeutic Role of Insulin in Acute Myocardial Infarction in Patients Admitted to Intensive Care and in Those With Unspecified Hyperglycemia. Diabetes Care, 2003, 26, 516-519.	4.3	59
140	Angiotensin II Receptor Blocker Valsartan Suppresses Reactive Oxygen Species Generation in Leukocytes, Nuclear Factor-IºB, in Mononuclear Cells of Normal Subjects: Evidence of an Antiinflammatory Action. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4496-4501.	1.8	198
141	Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. American Journal of Clinical Nutrition, 2002, 75, 767-772.	2.2	222
142	Insulin Resistance and Endothelial Dysfunction in Atherosclerosis: Implications and Interventions. Diabetes Technology and Therapeutics, 2002, 4, 809-815.	2.4	17
143	Tumor necrosis factor-[alpha] inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism: Clinical and Experimental, 2002, 51, 487-491.	1.5	104
144	A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. American Journal of Cardiology, 2002, 90, 27-33.	0.7	124

#	Article	IF	CITATIONS
145	Endothelium, inflammation, and diabetes. Current Diabetes Reports, 2002, 2, 311-315.	1.7	83
146	Insulin Inhibits Intranuclear Nuclear Factor κB and Stimulates IκB in Mononuclear Cells in Obese Subjects: Evidence for an Anti-inflammatory Effect?. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3257-3265.	1.8	610
147	Nuclear Factor-ήB Suppressive and Inhibitor-ήB Stimulatory Effects of Troglitazone in Obese Patients with Type 2 Diabetes: Evidence of an Antiinflammatory Action? ¹ . Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3250-3256.	1.8	125
148	The Suppressive Effect of Dietary Restriction and Weight Loss in the Obese on the Generation of Reactive Oxygen Species by Leukocytes, Lipid Peroxidation, and Protein Carbonylation1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 355-362.	1.8	308
149	Suppression of Nuclear Factor-κB and Stimulation of Inhibitor κB by Troglitazone: Evidence for an Anti-inflammatory Effect and a Potential Antiatherosclerotic Effect in the Obese. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1306-1312.	1.8	195
150	RAPID COMMUNICATION: Inhibitory Effect of a Two Day Fast on Reactive Oxygen Species (ROS) Generation by Leucocytes and Plasma Ortho-Tyrosine and Meta-Tyrosine Concentrations. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2899-2902.	1.8	85
151	Hydrocortisone Suppresses Intranuclear Activator-Protein-1 (AP-1) Binding Activity in Mononuclear Cells and Plasma Matrix Metalloproteinase 2 and 9 (MMP-2 and MMP-9). Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5988-5988.	1.8	41
152	Carvedilol Inhibits Reactive Oxygen Species Generation by Leukocytes and Oxidative Damage to Amino Acids. Circulation, 2000, 101, 122-124.	1.6	193
153	Glucose Challenge Stimulates Reactive Oxygen Species (ROS) Generation by Leucocytes. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2970-2973.	1.8	549
154	Increased lκB Expression and Diminished Nuclear NF-κB in Human Mononuclear Cells following Hydrocortisone Injection. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3386-3389.	1.8	35
155	Increase in Plasma Interleukin-10 Following Hydrocortisone Injection. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1141-1144.	1.8	30
156	Vasodilatory Effects of Troglitazone Improve Blood Pressure at Rest and During Mental Stress in Type 2 Diabetes Mellitus. Hypertension, 1999, 34, 83-88.	1.3	97
157	Insulin-induced vasodilatation of internal carotid artery. Metabolism: Clinical and Experimental, 1999, 48, 1470-1473.	1.5	30
158	Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor. Angiogenesis, 1998, 2, 93-104.	3.7	63
159	Effect of hydrocortisone on oxygen free radical generation by mononuclear cells. Metabolism: Clinical and Experimental, 1998, 47, 788-791.	1.5	51
160	Tumor Necrosis Factor-Î \pm in Sera of Obese Patients: Fall with Weight Loss. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2907-2910.	1.8	479
161	Insulin Attenuates Norepinephrine- Induced Venoconstriction. Hypertension, 1995, 25, 779-784.	1.3	70
1(0)			

162 Increase in Plasma Interleukin-10 Following Hydrocortisone Injection. , 0, .

#	Article	IF	CITATIONS
163	Insulin Inhibits the Pro-Inflammatory Transcription Factor Early Growth Response Gene-1 (Egr)-1 Expression in Mononuclear Cells (MNC) and Reduces Plasma Tissue Factor (TF) and Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations. , 0, .		85